Bone Therapeutics

Miguel Forte, M.D., Ph.D., CEO

Oct. 13 | 10:00am | BlueRock Therapeutics Ballroom

Gosselies, Belgium
(NASDAQ: BOTHE)

In-person Presentation
Bone Therapeutics is a listed, clinical-stage, cell therapy company committed to rebuilding the lives of patients suffering from debilitating bone and joint conditions. Leveraging its extensive expertise in mesenchymal stromal cells (MSCs), bone physiology, and patented manufacturing technology, Bone Therapeutics is developing a commercially ready, allogeneic, and off-the-shelf bone cell therapy platform, ALLOB, and a next-generation improved viscosupplement for osteoarthritic pain, JTA-004, which are designed to offer patients and physicians best-in-class treatment options. Currently in Phase II/III clinical development, Bone Therapeutics’ advanced product portfolio targets large orthopedic conditions with high unmet needs, such as knee osteoarthritis, unhealed fractures, and spinal fusion. Building on its allogeneic MSC platform, Bone Therapeutics recently broadened the product portfolio from orthopedics into inflammatory and other conditions.
www.bonetherapeutics.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions